The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases.
Int J Mol Sci
; 24(1)2022 Dec 25.
Article
in English
| MEDLINE | ID: covidwho-20243838
ABSTRACT
Diffuse parenchymal lung diseases (DPLD) or Interstitial lung diseases (ILD) are a heterogeneous group of lung conditions with common characteristics that can progress to fibrosis. Within this group of pneumonias, idiopathic pulmonary fibrosis (IPF) is considered the most common. This disease has no known cause, is devastating and has no cure. Chronic lesion of alveolar type II (ATII) cells represents a key mechanism for the development of IPF. ATII cells are specialized in the biosynthesis and secretion of pulmonary surfactant (PS), a lipid-protein complex that reduces surface tension and minimizes breathing effort. Some differences in PS composition have been reported between patients with idiopathic pulmonary disease and healthy individuals, especially regarding some specific proteins in the PS; however, few reports have been conducted on the lipid components. This review focuses on the mechanisms by which phospholipids (PLs) could be involved in the development of the fibroproliferative response.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Surfactants
/
Lung Diseases, Interstitial
/
Idiopathic Pulmonary Fibrosis
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Ijms24010326
Similar
MEDLINE
...
LILACS
LIS